Columbia Laboratories names new directors

Appointments follow recent acquisition of Molecular Profiles

Left to right: Jonathan Lloyd Jones, Vice President & CFO, Columbia Laboratories; Professor Martyn Davies, Chairman, Molecular Profiles; Frank C. Condella, President and CEO, Columbia Laboratories; Dr Nikin Patel, CEO, Molecular Profiles

Following its acquisition of UK-based pharmaceutical development services company Molecular Profiles, Columbia Laboratories has appointed three experienced healthcare executives with more than 65 years of collective industry experience to its Board of Directors, effective immediately.

Dr Frank Armstrong and Dr Nikin Patel have been appointed Directors of the company, and Dr Martyn Davies will serve as an Advisor to the company’s board. Drs. Davies and Patel are co-founders of Molecular Profiles.

'We are pleased to welcome Drs Armstrong, Patel and Davies to our Board of Directors,' said Steve Kasnet, chairman of Columbia’s Board of Directors. 'We look forward to benefiting from the insight and vast industry experience these knowledgeable individuals will bring.'

Dr Nikin Patel, CEO of Molecular Profiles, added: 'We are very pleased to join forces with Columbia Laboratories. We expect our current business will continue to grow, and we anticipate improving service to our many customers as part of a larger, well-capitalised, Nasdaq-listed company.'

'We are broadening our technical expertise with a management team that is well-recognised in the field of pharmaceutical development and analytical services,' commented Frank Condella, Columbia’s president and CEO. 'This dovetails with Columbia’s historical expertise with drug development, and should enable us to enhance our level of technical service to our commercial partners.'